My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
MEI Pharma (MEIP)
MEIP nasdaq
United States
MEI Pharma

MEI Pharma Stock Analysis & Ratings

MEI Pharma Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The MEI Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


MEIP Stock Stats

Previous Close$2.86
Bid2.83 x 2998
Ask2.87 x 2200
Today’s Range$2.83 - $2.87
52-Week Range$2.40 - $4.58
Average Volume478.43K
Market Cap$320.01M
P/E Ratio-4.1
Earnings DateNov 11, 2021

Company Description

MEI Pharma

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
Daniel P. Gold
11455 El Camino Real, San Diego, CA, 92130, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was MEI Pharma’s price range in the past 12 months?
MEI Pharma lowest stock price was $2.40 and its highest was $4.58 in the past 12 months.
    What is MEI Pharma’s market cap?
    MEI Pharma’s market cap is $320.01M.
      What is MEI Pharma’s price target?
      The average price target for MEI Pharma is $11.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $20.00 ,the lowest forecast is $8.00. The average price target represents 287.32% Increase from the current price of $2.84.
        What do analysts say about MEI Pharma?
        MEI Pharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is MEI Pharma’s upcoming earnings report date?
          MEI Pharma’s upcoming earnings report date is Nov 11, 2021 which is in 21 days.
            How were MEI Pharma’s earnings last quarter?
            MEI Pharma released its earnings results on Sep 02, 2021. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.169 by $0.119.
              Is MEI Pharma overvalued?
              According to Wall Street analysts MEI Pharma’s price is currently Undervalued.
                Does MEI Pharma pay dividends?
                MEI Pharma does not currently pay dividends.
                What is MEI Pharma’s EPS estimate?
                MEI Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does MEI Pharma have?
                MEI Pharma has 112,680,000 shares outstanding.
                  What happened to MEI Pharma’s price movement after its last earnings report?
                  MEI Pharma reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.169. Following the earnings report the stock price went up 2.12%.
                    Which hedge fund is a major shareholder of MEI Pharma?
                    Among the largest hedge funds holding MEI Pharma’s share is Driehaus Capital Management LLC. It holds MEI Pharma’s shares valued at N/A.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis